Navigation Links
Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy
Date:5/11/2012

warfarin therapy in 707 patients. 

The WATCHMAN Device was approved for marketing in Europe and other CE Mark countries in 2009.  Boston Scientific is currently enrolling U.S. patients in the PREVAIL study, a confirmatory study designed to gain U.S. Food and Drug Administration approval.  Enrollment is expected to be completed in the second quarter of 2012.  The WATCHMAN Device is contraindicated in patients who are not eligible for anticoagulation therapy.  In the U.S., the WATCHMAN Device is an investigational device, limited by applicable law to investigational use and not available for sale.  The device was developed by Atritech, which Boston Scientific acquired in March 2011.  For more information, visit www.Atritech.net.For more news about Boston Scientific at the Heart Rhythm Society 33rd Annual Scientific Sessions, please follow us on Twitter @BostonSci.

About Boston Scientific
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties.  For more information, please visit: www.bostonscientific.com.Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things,
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Study Shows NxStage Daily Home Hemodialysis Patients More Likely to Receive Kidney Transplant
2. Life Extension Foundation® study finds Cognitex® with NeuroProtection Complex may provide a positive impact on cognitive performance
3. Data from Study of Elderly Depressed Patients are Reported for Investigational Compound Lu AA21004 on Symptoms of Major Depressive Disorder (MDD)
4. Inaugural Harris Poll Physician Pulse(SM) Study: Viagra® and Cialis® are Highest Ranked in Trust
5. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
6. Staffing and Performance Benchmarks for Quality Function Highlight New Medical Device Study
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
9. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
10. National Study: Teen "Heavy" Marijuana Use Up 80 Percent Since 2008, One in Ten Teens Reports Using Marijuana at Least 20 Times a Month
11. Michael J. Fox Foundation-Funded Study Identifies Best Dyskinesia Clinical Rating Scale
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... Chief Executive Officer, will be presenting at the 26 th ... Palace Hotel in New York . The ... 2:00 PM ET. In addition, Mr. Krakauer and Jorgen ... separate one-on-one meetings during the day. An ...
(Date:11/21/2014)... November 2014 Michael DeMarco (42) ... des 14. Februar 2014 zugetragen hat. Seine Tochter Aly ... Video - http://youtu.be/5cVoMCe0uiE ... mein morgendliches Training zu machen", erzählt Michael DeMarco ... Zeit begeisterte Anhänger der CrossFit-Trainingsmethode. Ich war auf ...
(Date:11/21/2014)...   Wellcentive , the industry leader in ... announced today being named one of the four ... .  Sponsored by Intel, the world leader in ... recognizes companies developing leading-edge technology and unique approaches ... Wellcentive,s Mason Beard , senior ...
Breaking Medicine Technology:Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 2Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 3Wellcentive Named Finalist for 2014 Intel Innovation Award 2Wellcentive Named Finalist for 2014 Intel Innovation Award 3
... BETHESDA, Md., Nov. 1, 2011   For the first ... cause of cystic fibrosis, Kalydeco™ (ivacaftor), is under review ... approval in 2012. This milestone comes as the largest ... Anaheim, Calif., Nov. 3 – 5, 2011. ...
... the world,s leading provider of centralized expert assessments in ... disorders, announced it has been selected as one of ... NJBIZ, New Jersey,s premiere business news publication, annually identifies ... New Jersey,s most dynamic companies who progressively contribute to ...
Cached Medicine Technology:Anaheim to Host World's Largest Gathering on Cystic Fibrosis Research and Care 2MedAvante Is One of NJ's Fastest Growing Companies 2
(Date:11/23/2014)... NY (PRWEB) November 23, 2014 ... allege heart attacks, strokes, deep vein thrombosis and ... in a federal multidistrict litigation (MDL) underway in ... reports. , Court documents updated on November ... Litigation (JPML) show the filing of 259 lawsuits ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 Locks-Magnetic.com, a ... emergency doors. Moreover, all the new products are available ... The marketing manager is proud of the new emergency ... reset automatically. And customers can choose from several colors. ... Buying high quality emergency door release is not as ...
(Date:11/23/2014)... 23, 2014 SWAccessControl.com's high quality access ... Recently, the company has announced its new collection of ... on these high quality power suppliers. All the new ... The special offer lasts until Dec. 20, 2014. , ... them have been supporting it for a long time. ...
(Date:11/23/2014)... Newport Beach, CA (PRWEB) November 23, 2014 ... founder of American Medical Aesthetics & Wellness was ... Dr. Asher Milgrom, Ph.D. is president and CEO of ... Skincare. Dr. Asher Milgrom received a full scholarship ... Sciences and the Medical School at the University of ...
(Date:11/23/2014)... Syngenta lawsuits are now being investigated ... and agribusinesses that have allegedly incurred significant financial damages ... and Agrisure Duracade, genetically modified (GMO) corn seed ... in China. According to a report from Bloomberg News, ... corn imports. Because China is the third-largest American corn ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 3Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 3Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 4Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 2Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 3
... of using plant hormones to fight cancer cells. Plant need ... cuttings grow roots. Scientists at the Cancer Research Campaign (CRC), ... kill cancer cells. , Indole ... IAA are added with an enzyme, toxic by products, which ...
... itself by growing new cells after a heart attack. This ... Italy. Dr. Piero Anversa and colleagues of the New York ... called myocytes continued to divide after a heart attack. ... the hearts of 13 people who died within a few ...
... disease, that requires insulin injections daily. Researchers are slowly ... Some medical research centers in the U.S. and Europe ... by transplanting insulin-producing islet cells combined with less toxic ... lives without insulin. , A.M. ...
... size of children's tummies may offer a simple method of ... diabetes at a later age.Among adults, fat around the waist ... studies suggest that it is a better indicator of risk ... ,A large waist is said to be associated ...
... the brain and its function has always left man ... puzzle, some key factors// have been identified that could ... in premature babies and hence help treat prematurity. ... also prevent brain damage repair in neurological diseases like ...
... drinking coffee could decrease the risk of liver cancer.Researchers ... showed self-reported frequency of coffee consumption among more than ... researchers say they found that those who drink coffee ... while those drinking one or more cups a day ...
Cached Medicine News:Health News:Transplant helps diabetes 2Health News:Hyaluronic Acid – A Boon To The Problem Of Premature Infant 2
Nucleus chopper. For bimanual nucleus division....
Phaco chopper, a combination of a Sinskey hook and a pointed "quick chop" tip....
Phaco prechopper with blunt tip double-edge for bi-directional prechopping. For bimanual nucleus prechopping technique....
Titanium. A reverse action instrument with a paddle tips to provide a solid surface to crack the nucleus. When used in scleral tunnel, the reverse action mechanism allows increased flexibility in pos...
Medicine Products: